Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study

INTRODUCTION: Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI Pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoenberg, Paige, Edwards, O. Winslow, Merrill, Leland, Martinez, Cristian Acero, Stephenson, Rob, Sullivan, Patrick S., Jones, Jeb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034617/
https://www.ncbi.nlm.nih.gov/pubmed/36951057
http://dx.doi.org/10.1002/jia2.26077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034617/
https://www.ncbi.nlm.nih.gov/pubmed/36951057
http://dx.doi.org/10.1002/jia2.26077

Ejemplares similares